Expanding the treatment options of Superficial vein thrombosis with Rivaroxaban
|
|
- James O’Connor’
- 5 years ago
- Views:
Transcription
1 Expanding the treatment options of Superficial vein thrombosis with Rivaroxaban Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Faculty of Medicine, School of Health Sciences, University of Thessalia, Greece Chairman, Dept. of Vascular Surgery, University Hospital of Larissa Larissa, Greece
2 DISCLOSURES Participation in CALISTO Trial sponsored by GLAXO Honoraria from BAYER and Leo
3 Annual rate per 1000 SVT is a frequent disease STEPH 1 and EPI-GETBO 2 : Two French prospective epidemiological studies with comparable methodology [ ] 1.24 [ ] 0.60 [ ] SVT STEPH DVT EPI-GETBO PE EPI-GETBO 1. Frappé P. et al. J Thromb Haemost 2014; 12: Oger E. Thromb Haemost 2000; 83: DVT = deep vein thrombosis; PE = pulmonary embolism; SVT = superficial vein thrombosis.
4 Concomitant DVT or PE is frequent in patients with SVT at first presentation Setting Study POST [1.4] OPTIMEV [2,4] STEPH [3,4] Secondary/tertia ry Secondary/tertiary Primary No. of SVT patients Concomitant DVT or PE, % Concomitant DVT*, % Concomitant symptomatic PE, % *40 to 50% are proximal DVT, 40 to 45% are non-contiguous to SVT Systematic research of PE symptoms and ultrasonography 1. Decousus H. et al. Ann Intern Med 2010; 152: Galanaud JP. et al. Thromb Hemost 2011; 105: Frappé P. et al. J Thromb Hemost 2014; 12: Decousus H. et al. J Thromb Haemost 2015; 13 Suppl 1:S DVT = deep vein thrombosis; PE = pulmonary embolism; SVT = superficial vein thrombosis.
5 Patients with isolated SVT* are at significant risk of subsequent symptomatic DVT or PE at 3 6 months Study/setting Treatment received DVT, % PE, % STENOX 3 months, N = 427 VESALIO 3 months, N = 164 LMWH for 12 days in 50% LMWH for 30 days in all POST 3 months, N = 600 One or more anticoagulants in 90.5% (LMWH for a median of 11 days) OPTIMEV 3 months, N = 499 CALISTO* 77 days, N = 1,500 STEFLUX 3 months, N = 648 Van Weert 6 months, N = 185 Danish Registry 3 months, N = 10,973 Anticoagulants in 76.4% (for > 45 days in 24.6%) Placebo (patients at high risk excluded) * SVT without concomitant DVT or PE at first presentation. Decousus H. et al. J Thromb Haemost 2015; 13 Suppl 1:S LMWH for days in all No treatment in 83% No routine anticoagulant treatment DVT = deep vein thrombosis LMWH = low-molecular-weight heparin PE = pulmonary embolism SVT = superficial vein thrombosis
6 SVT close to SFJ
7 Guidelines (ACCP - International Consensus) Fondaparinux 2.5 mg daily for at least 4 weeks is an effective treatment (Grade 1b) LMWH in intermediate doses for at least one month is recommended (Grade 2a )
8 2010;363:
9 Fondaparinux for the treatment of superficial-vein thrombosis in the legs (Calisto) Décousus, H, Prandoni P, Mismetti P, Bauersachs R, Boda Z, Brenner N, Laporte S, Matyas L, Middeldord S, Sokurenko G, Leizorovicz A; N Engl J Med 2010; 363: 13: Inclusion Hospitalized or non-hospitalized patients 18 yrs With acute symptomatic SVT of the lower limbs at least 5 cm long and with thrombus head > 3 cm from the saphenofemoral or sapheno-popliteal junctions Confirmed by standard compression ultrasonography (CUS) Without concomitant DVT or PE at inclusion Able and willing to provide written informed consent Exclusion Symptomatic or asymptomatic DVT on qualifying CUS and/or PE SVT with thrombus head within 3 cm from the sapheno-femoral or sapheno-popliteal junctions SVT with an history of documented DVT/PE within the last 6 months SVT in patients with active cancer i.e. cancer within the last 6 months SVT in severe renal impairment (<30 ml/min) Treatment with anticoagulant therapy > 48 hours prior to inclusion Requirement for ligation of the sapheno-femoral junction or thrombectomy SVT following sclerotherapy or resulting as a complication of an IV line
10 Primary Outcomes Primary efficacy outcome: Composite of symptomatic thromboembolic complications and all-cause death up to Day 47 in all randomized patients (ITT) Symptomatic non-fatal (confirmed by CT or V/Q scans) or fatal PE Symptomatic DVT (confirmed by CUS) Symptomatic extension of the initial SVT, at 3 cm from the saphenofemoral junction (confirmed by CUS) Symptomatic recurrent SVT (confirmed by CUS) All-cause death Primary safety outcome: Major bleeding and death up to Day 47 in all randomized patients having received 1 treatment dose
11 CALISTO study The primary efficacy outcome at day 47 (death from any cause or symptomatic PE, symptomatic DVT, or symptomatic extension to the saphenofemoral junction or symptomatic recurrence of DVT) occurred in 0.9% of patients in the fondaparinux group and 5.9% in the placebo group (P < 0.001). The rate of PE or DVT was 85% lower in the fondaparinux group at day 47. Similar risk reductions were observed at day 77. No difference was observed in major bleeding between the two groups. Decousus H et al. CALISTO Study Group. N Engl J Med 2010;363:
12 Placebo-controlled study (CALISTO) with clinical outcome in SVT patients patients with isolated SVT Placebo 45 days Primärer Wirksamkeits-Endpunkt HR, 0,14 (95% CI, 0,08 to 0,26; p<0,001) 2.5 mg Fondaparinux End of treatment Behandlungsende Death Tödlich Severe Schwer Clin Klin.relev. rel. Light Leicht all Gesamt Safety endpoint: bleeding (%) 0 0,5 1 Tage Décousus H, Prandoni, P, Mismetti, P, Bauersachs R, Boda, Z, et al. : N Engl J Med. 2010;363(13): Fondaparinux Plazebo
13 Goldman and Ginsberg. NEJM 2010;363:1278 Historical comparisons have shown extremely low mortality among untreated pts with SVT, which supports an initial no anticoagulation treatment approach unless conservative measures fail to resolve symptoms or DVT develops Treatment with Fondaparinux for 45 days may be reasonable in case of severe symptoms, thrombosis in the proximal saphenous vein, or in recurrent disease Cost-effectiveness issues Therapy with Fondaparinux 2.5 mg daily for 45 days costs $2,124 to $7,380
14 3-month incidence of symptomatic VTE (%) CALISTO in Real-world practice , , , , , p=0.06 DVT or PE DVT PE Patients that could have been included in CALISTO Patients that would not have been included in CALISTO Décousus H, Leizorovicz A, Bauersachs R, et al: N Engl J Med 2010; 363: Galanaud JP, J Thromb Haemost 2012; 10: Galanaud JP. The OPTIMEV study. Thromb Haemost 2011; 105: 31-9.
15 CALISTO: High-risk patients In the placebo group, subgroup analyses showed an increased incidence of symptomatic VTE complications at Day 47 (primary efficacy endpoint) in patients presenting one of the following characteristics at inclusion: Age > 75 yrs BMI 30 kg/m 2 CrCl < 50 ml/min History of DVT/PE (> 6 months previously) History of SVT (> 3 months previously) Absence of varicose veins at inclusion SVT abovethe knee SVT involving the great saphenous vein Distance between the thrombus head and the SFJ < 10 cm Decousus H. et al. for the CALISTO Study Group. N Engl J Med 2010; 363: BMI = body mass index; CrCl = creatinine clearance; DVT = deep vein thrombosis; PE = pulmonary embolism; SFJ = sapheno-femoral junction; SVT = superficial vein thrombosis; VTE = venous thromboembolism.
16 Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial Werth S, Bauersachs R, Gerlach H, Rabe E, Schellong S, Beyer- Westendorf J J Thromb Thrombolysis (2016) 42: Open-label, masked endpoint, randomised, non-inferiority phase 3b trial Patients aged 18 years or older with symptomatic superficialvein thrombosis 27 sites (academic, community hospitals, and specialist practices) in Germany. Randomly assigned patients (1:1) to receive 10 mg oral rivaroxaban or 2 5 mg subcutaneous fondaparinux once a day for 45 days.
17 Inclusion criteria Acute symptomatic supragenicular SVT of the leg And at least one of the following risk factors Age over 65 years Male sex History of DVT/PE/SVT History of cancer or active cancer Autoimmune disease SVT of non-varicose veins Thrombus extension of at least 5 cm Proximal thrombus end with more than 3 cm distance to the saphenofemoral junction (SFJ) Age over 18 years Written informed consent
18 Efficacy outcome Primary Composite of death from any cause symptomatic PE (objectively confirmed by ventilationperfusion scanning, helical computed tomography, pulmonary angiography, or autopsy) symptomatic DVT (confirmed by ultrasonography or venography) symptomatic SVT extension towards the saphenofemoral junction symptomatic SVT recurrence (confirmed by ultrasonography) up to day 47 Secondary the composite primary efficacy outcome up to day 90 the separate items of the primary efficacy outcome up to day 47 and day 90 the rate of symptomatic pulmonary embolism, symptomatic proximal DVT, VTE-related death the rates of emergency surgery for SVT
19 Safety outcome Primary Clinically overt major bleeding according to the ISTH definition, defined as an overt bleeding that is either associated with a fall of haemoglobin of 2 g/l or more, leading to a transfusion of 2 or more units of packed red blood cells or whole blood occurring into a critical site such as intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal fatal bleeding. Secondary Clinically relevant non-major, minor and any bleeding and death from any cause. Clinically relevant, non-major bleeding (ISTH definition): any overt bleeding that is associated with a medical intervention by a healthcare professional, or an unscheduled physician s contact (presence or telephone contact), a temporary or complete cessation of study drug, any relevant discomfort to the patient (pain, impairment of activities of daily life).
20 Fondaparinux vs. Rivaroxaban in SVT patients with a higher VTE-risk : SURPRISE-Study SVT in the thigh and Age > 65 years or Male gender or Previous DVT/PE/SVT or History of or active cancer or Autoimmunologic disease or SVT in non-varicose veins or 472 risk-patients with isolated SVT Rivaroxaban 10 mg 2.5 mg 45 days Fondaparinux J. Beyer-Westendorf,SM Schellong, H. Gerlach, E. Rabe, J.I. Weitz, K. Jersemann, K. Sahin, R. Bauersachs THE LANCET HAEMATOLOGY-D S (17)
21 Patients and results
22 Fondaparinux vs. Rivaroxaban in SVT patients with a higher VTE-risk : SURPRISE-Study SVT in the thigh and Age > 65 years or Male gender or Previous DVT/PE/SVT or History of or active cancer or Autoimmunologic disease or SVT in non-varicose veins or 472 risk-patients with isolated SVT Rivaroxaban 10 mg 2.5 mg Fondaparinux 45 days HR, 1.1(0.5 to 2.2); p=0.047 for non-inferiority HR 6.1;( ) days days J. Beyer-Westendorf,SM Schellong, H. Gerlach, E. Rabe, J.I. Weitz, K. Jersemann, K. Sahin, R. Bauersachs THE LANCET HAEMATOLOGY-D S (17)
23 Conclusions 1 In patients on higher risk Rivaroxaban 10 mg od is not inferior to Fondaparinux 2.5 mg od in preventing overall VTE complications in SVT patients (3% vs. 2%) During treatment in both groups VTE was very rare but DVT occured slightly more frequent in the Rivaroxaban group (3/211 vs. 1/224) During follow up a rebound phenomenon was present in both groups resulting in primary efficacy outcome after 90 days in 15 patients (7%) in both groups Again DVT was more frequent in the Rivaroxaban group (6/211 vs. 2/224) No PE occured
24 Conclusions 2 Adverse events where rare in both groups No major bleeding occured The incidence of minor bleeding until day 45 was the same in both groups (6%) Clinically relevant non-major bleeding occured more often in the Rivaroxaban group (6/211 vs. 1/224)
25 Conclusions 3 Low dose (prophylactic dosage) of Rivaroxaban or Fondaparinux is effective in preventing VTE complications in SVT SVT patients on higher risk for VTE complications (SURPRISE) may benefit from anticoagulation longer than 45 days compared to low risk patients (CALISTO)
26 Summary SVT is part of VTE like DVT and PE VTE complications of SVT are frequent In patients with a low risk 45 days of a prophylactic dose of fondaparinux is enough High risk patients may need a prolonged treatment Pooled analyses of outcome studies are neededto better identify «risk-partients»
27 Thank you very much for the attention
Current issues in the management of Superficial Vein Thrombosis - SVT
Current issues in the management of Superficial Vein Thrombosis - SVT Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Faculty of Medicine, School of Health Sciences,
More informationWhat is the impact of Superficial Vein Thrombosis?
What is the impact of Superficial Vein Thrombosis? Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Faculty of Medicine, University of Thessalia, Greece Chairman,
More informationSuperficial Thrombophlebitis Treatment Guideline Review
Superficial Thrombophlebitis Treatment Guideline Review Suman M. Wasan, MD, MS Regents Professor Director, Vascular Medicine College of Medicine University of Oklahoma Health Sciences Center Disclosure
More informationSupplementary Online Content
Supplementary Online Content Mismetti P, Laporte S, Pellerin O, Ennezat P-V, Couturaud F, Elias A, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone
More informationControversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis
CONTROVERSIES IN VENOUS THROMBOEMBOLISM: TO TREAT OR NOT TO TREAT Controversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis Jan Beyer-Westendorf Thrombosis Research
More informationTrombosi venose superficiali e trombosi venose distali
XXIV Congresso Nazionale SISET Abano 9-12 Novembre 2016 Trombosi venose superficiali e trombosi venose distali Gualtiero Palareti / Benilde Cosmi Università di Bologna Superficial vein thrombosis (SVT):
More informationKeynote lecture: Oral anticoagulation and DVT
Keynote lecture: Oral anticoagulation and DVT What is the evidence? Is there a need to anticoagulate every lower leg DVT? Disclosure Speaker name:...sebastian Schellong... I have the following potential
More informationThe legally binding text is the original French version. Opinion 15 May 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 15 May 2013 ARIXTRA 2.5 mg/0.5 ml, solution for injection in pre-filled syringe B/2 (CIP: 34009 359 225 4 0) B/7 (CIP:
More informationAnticoagulation Forum: Management of Tiny Clots
Anticoagulation Forum: Management of Tiny Clots Casey O Connell, MD FACP Associate Professor Jane Anne Nohl Division of Hematology Keck School of Medicine USC DISCLOSURES None 4/11/2017 Objectives Define
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationWith All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis
BRIGHAM AND WOMEN S HOSPITAL With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis Gregory Piazza, MD, MS Division of Cardiovascular Medicine Brigham and Women s Hospital April
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC 1 st workshop: update to VTE guidelines in 2016 2 nd workshop: VTE controversies + new horizons André Roussin MD, FRCP, CSPQ CHUM
More informationBenefit risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism
Review Article 231 Benefitrisk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism Jan Beyer-Westendorf 1 ; Walter Ageno 2 1 Center for Vascular Diseases
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationRapid Fire-Top Articles You Need to Know
Rapid Fire-Top Articles You Need to Know TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE- SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE
More informationCURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow
CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired
More informationImplications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach
Implications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach Prof. I. Baumgartner Head Clinical and Interventional Angiology About the ACCP guidelines Widely
More informationDuration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium
Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium Disclosures Honoraria and research support: Daiichi-Sankyo, Boehringer Ingelheim,
More informationClinical Cases with Deep Venous Thrombosis - The position of Apixaban Stavros KAKKOS, MD, MSc, PhD, RVT
Clinical Cases with Deep Venous Thrombosis - The position of Apixaban Stavros KAKKOS, MD, MSc, PhD, RVT Department of Vascular Surgery. University Hospital of Patras Chairman: Ioannis Tsolakis DISCLAIMER
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 16 December 1999 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON CLINICAL
More informationThe latest on the diagnosis and treatment of venous thromboembolism
The latest on the diagnosis and treatment of venous thromboembolism Vicky Tagalakis MD FRCP Division of General Internal Medicine Jewish General Hospital McGill University Disclosures Advisory board Pfizer
More informationUpdates in venous thromboembolism. Cecilia Becattini University of Perugia
Updates in venous thromboembolism Cecilia Becattini University of Perugia News for VTE Diagnosis Treatment the acute phase the agents Pulmonary embolism: diagnosis Vein ultrasonography Meta-analysis 15
More informationOral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study.
Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study Comments Harald Darius, Berlin Disclosures for Harald Darius Research
More informationFocus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular
More informationThe clinical relevance of AMPLIFY programme
Venice October 16th 2015 The clinical relevance of AMPLIFY programme Francesco Dentali Department of Clinical Medicine Insubria University Varese Disclosures Bayer Bristol-Myers Squibb/Pfizer Boehringer
More informationStatus of anticoagulation therapy in 2016: Is there a need for venous revascularization?
Status of anticoagulation therapy in 2016: Is there a need for venous revascularization? Rupert M. Bauersachs Dept. of Vascular Medicine, Darmstadt Center of Thrombosis Hemostasis, Mainz Status of anticoagulation
More informationDiagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism
Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism Summary Number 68 Overview Venous thromboembolism
More informationUpdates in Diagnosis & Management of VTE
Updates in Diagnosis & Management of VTE Financial Disclosures-NONE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE- SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA,
More informationEXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS
EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine Harvard Medical
More informationPULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT
PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT OBJECTIVE: To provide a diagnostic algorithm and treatment options for patients with acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE)
More informationPrimary VTE Prophylaxis. Ponlapat Rojnuckarin, MD PhD Chulalongkorn University Bangkok, Thailand
Primary VTE Prophylaxis Ponlapat Rojnuckarin, MD PhD Chulalongkorn University Bangkok, Thailand A 70-yr-old female before THA BMI 31 kg/m 2 with varicose vein What do you recommend for VTE prevention?
More informationCancer Associated Thrombosis: six months and beyond. Farzana Haque Hull York Medical School
Cancer Associated Thrombosis: six months and beyond Farzana Haque Hull York Medical School Disclosure I have no disclosure The Challenge of Anticoagulation in Patients with Venous Thromboembolism and Cancer
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationDVT - initial management NSCCG
Background information Information resources for patients and carers Updates to this care map Synonyms Below knee DVT and bleeding risks Patient with confirmed DVT Scan confirms superficial thrombophlebitis
More informationVenous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community
Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer
More informationDuration of anticoagulation
Duration of anticoagulation P. Fontana Service d angiologie et d hémostase Hôpitaux Universitaires de Genève Pomeriggio formativo in coagulazione, Bellinzona, 19.10.2017 Conflict of interest AstraZeneca,
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationCHAPTER 2 VENOUS THROMBOEMBOLISM
CHAPTER 2 VENOUS THROMBOEMBOLISM Objectives Venous Thromboembolism (VTE) Prevalence Patho-physiology Risk Factors Diagnosis Pulmonary Embolism (PE) Management of DVT/PE Prevention VTE Patho-physiology
More informationNOAC s across indications
Sektion CAMPUS INNENSTADT Med. Klinik und Poliklinik IV NOAC s across indications Ulrich Hoffmann, M.D. Division of Vascular Medicine University Hospital Munich, Germany Disclosure Speaker name: Ulrich
More informationARTEMIS. ARixtra (fondaparinux) for ThromboEmbolism prevention in. a Medical Indications Study. NV Organon Protocol 63129
ARTEMIS ARixtra (fondaparinux) for ThromboEmbolism prevention in NV Organon Protocol 63129 a Medical Indications Study Objective To demonstrate efficacy and to assess safety of oncedaily subcutaneous (SC)
More informationSimplified approach to investigation of suspected VTE
Simplified approach to investigation of suspected VTE Diagnosis of DVT and PE THSNA 2016, Chicago 15 April 2016 Clive Kearon, McMaster University, Canada Relevant Disclosures Research Support/P.I. Employee
More informationInferior Venacaval Filters Valuable vs. Dangerous Valuable Annie Kulungowski. Department of Surgery Grand Rounds March 24, 2008
Inferior Venacaval Filters Valuable vs. Dangerous Valuable Annie Kulungowski Department of Surgery Grand Rounds March 24, 2008 History of Vena Cava Filters Virchow-1846-Proposes PE originate from veins
More informationCanadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON
Canadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON How to Prevent and Manage the Post-Thrombotic Syndrome? Jean-Philippe Galanaud Clinical Thromboembolism & Division of GIM Sunnybrook,
More informationMedical Patients: A Population at Risk
Case Vignette A 68-year-old woman with obesity was admitted to the Medical Service with COPD and pneumonia and was treated with oral corticosteroids, bronchodilators, and antibiotics. She responded well
More informationDisclosures. What is a Specialty Vein Clinic? Prevalence of Venous Disease. Management of Venous Disease: an evidence based approach.
Management of Venous Disease: an evidence based approach Disclosures Ed Boyle, MD Andrew Jones, MD Dr. Ed Boyle and Dr. Andrew Jones disclose Grants/research support: Medtronic, BTG International, Clearflow,
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationDisclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None
Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationInferior Vena Cava Filters
Inferior Vena Cava Filters and the American Society of Hematology Choosing Wisely Campaign Kevin P. Hubbard, DO, HMDC MACOI Chief - Division of Specialty Medicine Professor and Chair - Section of Internal
More informationThrombosis. Tom DeLoughery, MD FACP. Oregon Health and Sciences University
Thrombosis Tom DeLoughery, MD FACP Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen, Alexion What I am Talking About New Anticoagulants
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: The EINSTEIN PE Investigators. Oral rivaroxaban for the treatment of
More informationWhen and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD
When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD December 12, 2015 Disclosures CONSULTANT Merck; New Haven
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationUnderstanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR
Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine
More informationAcute and long-term treatment of VTE. Cecilia Becattini University of Perugia
Acute and long-term treatment of VTE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE The goals The acute PE phase After the acute phase Treatment for VTE Goals of acute treatment
More informationAspirin as Venous Thromboprophylaxis
Canadian Society of Internal Medicine Nov 2, 2017 Aspirin as Venous Thromboprophylaxis Bill Geerts, MD, FRCPC Thromboembolism Consultant, Sunnybrook HSC Professor of Medicine, University of Toronto Disclosures
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationC. Michael Gibson, M.S., M.D. Professor of Medicine Harvard Medical School
Novel Strategies to Prevent Pulmonary Embolism and DVT: APEX Trial and Substudies C. Michael Gibson, M.S., M.D. Professor of Medicine Harvard Medical School Conflict of Interest Statement 2 Present Research/Grant
More informationDeep Venous Pathology. Eberhard Rabe Department of Dermatology University of Bonn Germany
Deep Venous Pathology Eberhard Rabe Department of Dermatology University of Bonn Germany Disclosures None for this presentation Consultant: Sigvaris, EUROCOM Speakers bureau: Bayer Vital, Aspen, Boehringer,
More informationA Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism
Cardiol Ther (2018) 7:1 13 https://doi.org/10.1007/s40119-018-0107-0 REVIEW A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism Andrew
More informationNew Perspective in VTE Treatment in Acute Medically Ill Patients: Single vs. Dual Drug Approach. Dr. Johan Kurnianda, SpPD-KHOM
New Perspective in VTE Treatment in Acute Medically Ill Patients: Single vs. Dual Drug Approach Dr. Johan Kurnianda, SpPD-KHOM VTE : Spectrum of Disease Deep Vein Thrombosis Post Thrombotic Syndrome Pulmonary
More informationVTE Management in Surgical Patients: Optimizing Prophylaxis Strategies
VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies VTE in Surgical Patients: Recognizing the Patients at Risk Pathogenesis of thrombosis: Virchow s triad and VTE Risk Hypercoagulability
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationUnderstanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal
Understanding thrombosis in venous thromboembolism João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Disclosures João Morais On the last year JM received honoraria
More informationSCIENTIFIC DISCUSSION
London, 25 January 2005 Product name: Arixtra Procedure No. EMEA/H/C/403/II/10 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86
More informationCANCER ASSOCIATED THROMBOSIS. Pankaj Handa Department of General Medicine Tan Tock Seng Hospital
CANCER ASSOCIATED THROMBOSIS Pankaj Handa Department of General Medicine Tan Tock Seng Hospital My Talk Today 1.Introduction 2. Are All Cancer Patients at Risk of VTE? 3. Should All VTE Patients Be Screened
More informationVenous Thrombo-Embolism. John de Vos Consultant Haematologist RSCH
Venous Thrombo-Embolism John de Vos Consultant Haematologist RSCH overview The statistics Pathogenesis Prophylaxis Treatment Agent Duration Incidental VTE Recurrence of VTE IVC filters CVC related thrombosis
More informationEffectiveness and Safety of Direct Oral Anticoagulants and Warfarin Among Patients with Sickle Cell Disease: A Retrospective Cohort Study
Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin Among Patients with Sickle Cell Disease: A Retrospective Cohort Study Megan Roberts, PharmD, BCPS MUSC Medical Center and South Carolina
More informationVenous thromboembolic diseases: diagnosis, management and thrombophilia testing (2012) NICE guideline CG144
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (2012) NICE guideline CG144 Appendix A: Summary of new evidence from Summary of evidence from previous year Diagnosis Diagnostic
More informationTop 5 (or so) Hematology Consults. Tom DeLoughery, MD FACP FAWM. Oregon Health and Sciences University DISCLOSURE
Top 5 (or so) Hematology Consults Tom FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none 1 What I am Talking About
More informationEpidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005
Cancer and Venous Thromboembolism Objectives 1. Epidemiology of thrombosis in patients with malignancy 2. Anticancer agents and thrombosis 3. Current treatment protocols at UHN 4. Prevention of DVT 5.
More informationAnticoagulation therapy following endovascular treatment of iliofemoral deep vein thrombosis
Anticoagulation therapy following endovascular treatment of iliofemoral deep vein thrombosis Tim Sebastian, M.D. University Hospital Zurich Clinic for Angiology Disclosure Speaker name: Tim Sebastian I
More informationDeep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H
Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H Authors' objectives To systematically review the incidence of deep vein
More informationUSE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY
SDSHP ANNUAL MEETING CLINICAL PEARLS APRIL 7 TH, 2017 USE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY STEFFANIE DANLEY, PHARM D, BCPS, CACP DISCLOSURE I have had no financial relationship over the past 12
More informationIliofemoral DVT: Miminizing Post-Thrombotic Syndrome
Iliofemoral DVT: Miminizing Post-Thrombotic Syndrome Catherine K. Chang, MD FACS Vascular Surgery San Diego Southern California Permanente Medical Group Acute Deep Venous Thrombosis Incidence & Outcomes
More informationPOINT OF CARE ULTRASOUND - Venous US for DVT
POINT OF CARE ULTRASOUND - Venous US for DVT The diagnosis of deep venous thrombosis (DVT) using ultrasound in the emergency department. DVT US is easy to perform and can be usually be completed in less
More informationVenous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital
Venous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital VTE is common and dangerous 5 VTE is Common VTE Incidence: 1.5 / 1000 per year
More informationUpdates in Management of Venous Thromboembolic Disease
Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures
More informationVenous Thromboembolic Disease Update
Canadian Society of Internal Medicine Annual Meeting Calgary, Alberta, October 2014 Venous Thromboembolic Disease Update Benjamin Bell, MD FRCPC James Douketis, MD FRCPC On Behalf of Thrombosis Canada
More informationReduced-dosed Rivaroxaban in the long-term prevention of recurrent symptomatic DVT The Einstein-Choice trial
Reduced-dosed Rivaroxaban in the long-term prevention of recurrent symptomatic DVT The Einstein-Choice trial Thomas HW Stadlbauer Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar,
More informationAnticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism
Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism Annie Young PhD Professor of Nursing, University of Warwick, UK on behalf of the select-d Collaborative
More informationPerioperative Management of the Anticoagulated Patient
Perioperative Management of the Anticoagulated Patient Citywide Resident Perioperative Medical Consultation Conference 5/5/17 Matthew Eisen, MD Director, Anticoagulation Services MetroHealth Medical Center
More informationThe Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for
The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for Anticoagulation Services Sanford USD Medical Center Sioux Falls,
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationNew areas of development for the direct oral anticoagulants
New areas of development for the direct oral anticoagulants Varese March 2016 Disclosures for Harry R Büller Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory
More informationPulmonary Thromboembolism
Pulmonary Thromboembolism James Allen, MD Epidemiology of Pulmonary Embolism 1,500,000 new cases per year in the United States Often asymptomatic 300,000 deaths per year DVT or PE present in 10% of ICU
More informationDiagnosis and Management of Venous Thromboembolism
Diagnosis and Management of Venous Thromboembolism Muhammad Sajid Pervaiz Consultant Haematologist Chairman VTE committee Pennine Acute Hospitals NHS trust TOPICS 1-Introduction (Seriousness of problem)
More informationPrevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales
Prevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales Merimbula, 6 th November 2010 University of Sydney Department of Surgery Westmead Hospital
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationNew Anticoagulants and Emerging Strategies
New Anticoagulants and Emerging Strategies in the Treatment of Venous Thromboembolism b Stavros V. Konstantinides, MD, PhD, FESC Head, Department of Cardiology, Democritus University of Thrace, Greece
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationDuration of Therapy for Venous Thromboembolism
Duration of Therapy for Venous Thromboembolism Michael B Streiff, MD FACP Associate Professor of Medicine and Pathology Medical Director, Johns Hopkins Anticoagulation Service Chairman, VTE Guideline Committee
More informationACR Appropriateness Criteria Suspected Lower Extremity Deep Vein Thrombosis EVIDENCE TABLE
. Fowkes FJ, Price JF, Fowkes FG. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg 003; 5():-5.. Hamper UM, DeJong MR, Scoutt LM. Ultrasound
More informationOral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism (Review)
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism (Review) Robertson L, Kesteven P, McCaslin JE This is a reprint of a Cochrane review, prepared and maintained
More informationThe Evidence Base for Treating Acute DVT
The Evidence Base for Treating Acute DVT Mr Chung Sim Lim Consultant Vascular Surgeon and Honorary Lecturer Royal Free London NHS Foundation Trust and University College London NIHR UCLH Biomedical Research
More informationAcute and long-term treatment of PE. Cecilia Becattini University of Perugia
Acute and long-term treatment of PE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE What is the optimal acute phase treatment for the patient? Intravenous thrombolysis One
More information